STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth

Jingjing Gong, Amanda R. Muñoz, Daniel Chan, Rita Ghosh, Addanki P Kumar

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The dismal 5-year survival (<5%) for pancreatic cancer (PanCA) underscores the need for developing effective therapeutic options. Recent studies from our laboratory have shown that Nexrutine® (Nx), a bark extract from Phellodendron amurense exhibits excellent anticancer activity in human pancreatic cancer cells through inhibition of inflammatory signaling via STAT3/NF?B/Cox-2. Given the apparent high oxidative stress and autophagic activity in pancreatic tumors, we investigated the potential of Nx to modulate autophagy, reactive oxygen species (ROS), and their crosstalk. Our results show that Nx inhibits autophagy and decreases ROS generation. Pharmacological inhibition of autophagy led to decreased ROS generation and proliferation with no significant effect on apoptosis. Further, using combination index analysis we also found that combination of late-stage autophagy inhibitor with Nx exhibited a moderate synergistic to additive effect. Additionally, genetic or pharmacological inactivation of STAT3 reduced LC3-II levels and expression indicating a possible role for STAT3 in transcriptional regulation of autophagy. Since both inflammatory and oxidative stress signaling activate STAT3, our data implicates that STAT3 plays a vital role in the regulation of autophagy through its contributions to the positive feedback loop between ROS and autophagy. Overall, our findings reveal an important role for STAT3/LC3/ROS in Nx-mediated anti-pancreatic cancer effects.

Original languageEnglish (US)
Pages (from-to)2529-2541
Number of pages13
JournalOncotarget
Volume5
Issue number9
StatePublished - 2014

Fingerprint

Autophagy
Pancreatic Neoplasms
Down-Regulation
Reactive Oxygen Species
Growth
Phellodendron
Oxidative Stress
Pharmacology
Human Activities
Nexrutine
Apoptosis
Neoplasms

Keywords

  • Autophagy
  • Inflammation
  • LC3
  • Nexrutine®
  • Pancreatic cancer
  • STAT3

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth. / Gong, Jingjing; Muñoz, Amanda R.; Chan, Daniel; Ghosh, Rita; Kumar, Addanki P.

In: Oncotarget, Vol. 5, No. 9, 2014, p. 2529-2541.

Research output: Contribution to journalArticle

Gong, Jingjing ; Muñoz, Amanda R. ; Chan, Daniel ; Ghosh, Rita ; Kumar, Addanki P. / STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth. In: Oncotarget. 2014 ; Vol. 5, No. 9. pp. 2529-2541.
@article{e4b8380a2ed54116a651fc3bd3ec533b,
title = "STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth",
abstract = "The dismal 5-year survival (<5{\%}) for pancreatic cancer (PanCA) underscores the need for developing effective therapeutic options. Recent studies from our laboratory have shown that Nexrutine{\circledR} (Nx), a bark extract from Phellodendron amurense exhibits excellent anticancer activity in human pancreatic cancer cells through inhibition of inflammatory signaling via STAT3/NF?B/Cox-2. Given the apparent high oxidative stress and autophagic activity in pancreatic tumors, we investigated the potential of Nx to modulate autophagy, reactive oxygen species (ROS), and their crosstalk. Our results show that Nx inhibits autophagy and decreases ROS generation. Pharmacological inhibition of autophagy led to decreased ROS generation and proliferation with no significant effect on apoptosis. Further, using combination index analysis we also found that combination of late-stage autophagy inhibitor with Nx exhibited a moderate synergistic to additive effect. Additionally, genetic or pharmacological inactivation of STAT3 reduced LC3-II levels and expression indicating a possible role for STAT3 in transcriptional regulation of autophagy. Since both inflammatory and oxidative stress signaling activate STAT3, our data implicates that STAT3 plays a vital role in the regulation of autophagy through its contributions to the positive feedback loop between ROS and autophagy. Overall, our findings reveal an important role for STAT3/LC3/ROS in Nx-mediated anti-pancreatic cancer effects.",
keywords = "Autophagy, Inflammation, LC3, Nexrutine{\circledR}, Pancreatic cancer, STAT3",
author = "Jingjing Gong and Mu{\~n}oz, {Amanda R.} and Daniel Chan and Rita Ghosh and Kumar, {Addanki P}",
year = "2014",
language = "English (US)",
volume = "5",
pages = "2529--2541",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "9",

}

TY - JOUR

T1 - STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth

AU - Gong, Jingjing

AU - Muñoz, Amanda R.

AU - Chan, Daniel

AU - Ghosh, Rita

AU - Kumar, Addanki P

PY - 2014

Y1 - 2014

N2 - The dismal 5-year survival (<5%) for pancreatic cancer (PanCA) underscores the need for developing effective therapeutic options. Recent studies from our laboratory have shown that Nexrutine® (Nx), a bark extract from Phellodendron amurense exhibits excellent anticancer activity in human pancreatic cancer cells through inhibition of inflammatory signaling via STAT3/NF?B/Cox-2. Given the apparent high oxidative stress and autophagic activity in pancreatic tumors, we investigated the potential of Nx to modulate autophagy, reactive oxygen species (ROS), and their crosstalk. Our results show that Nx inhibits autophagy and decreases ROS generation. Pharmacological inhibition of autophagy led to decreased ROS generation and proliferation with no significant effect on apoptosis. Further, using combination index analysis we also found that combination of late-stage autophagy inhibitor with Nx exhibited a moderate synergistic to additive effect. Additionally, genetic or pharmacological inactivation of STAT3 reduced LC3-II levels and expression indicating a possible role for STAT3 in transcriptional regulation of autophagy. Since both inflammatory and oxidative stress signaling activate STAT3, our data implicates that STAT3 plays a vital role in the regulation of autophagy through its contributions to the positive feedback loop between ROS and autophagy. Overall, our findings reveal an important role for STAT3/LC3/ROS in Nx-mediated anti-pancreatic cancer effects.

AB - The dismal 5-year survival (<5%) for pancreatic cancer (PanCA) underscores the need for developing effective therapeutic options. Recent studies from our laboratory have shown that Nexrutine® (Nx), a bark extract from Phellodendron amurense exhibits excellent anticancer activity in human pancreatic cancer cells through inhibition of inflammatory signaling via STAT3/NF?B/Cox-2. Given the apparent high oxidative stress and autophagic activity in pancreatic tumors, we investigated the potential of Nx to modulate autophagy, reactive oxygen species (ROS), and their crosstalk. Our results show that Nx inhibits autophagy and decreases ROS generation. Pharmacological inhibition of autophagy led to decreased ROS generation and proliferation with no significant effect on apoptosis. Further, using combination index analysis we also found that combination of late-stage autophagy inhibitor with Nx exhibited a moderate synergistic to additive effect. Additionally, genetic or pharmacological inactivation of STAT3 reduced LC3-II levels and expression indicating a possible role for STAT3 in transcriptional regulation of autophagy. Since both inflammatory and oxidative stress signaling activate STAT3, our data implicates that STAT3 plays a vital role in the regulation of autophagy through its contributions to the positive feedback loop between ROS and autophagy. Overall, our findings reveal an important role for STAT3/LC3/ROS in Nx-mediated anti-pancreatic cancer effects.

KW - Autophagy

KW - Inflammation

KW - LC3

KW - Nexrutine®

KW - Pancreatic cancer

KW - STAT3

UR - http://www.scopus.com/inward/record.url?scp=84901217743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901217743&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 2529

EP - 2541

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 9

ER -